鼻用コルチコステロイドの世界市場

鼻用コルチコステロイドの世界市場は2030年までに84億米ドルに達する

2024年に67億米ドルと推定される鼻用コルチコステロイドの世界市場は、2024～2030年の分析期間にCAGR 3.7%で成長し、2030年には84億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるプロピオン酸フルチカゾンは、CAGR 4.9%を記録し、分析期間終了時には38億米ドルに達すると予測されます。ブデソニド分野の成長率は、分析期間中CAGR 2.5%と推定されます。

米国市場は18億米ドルと推定、中国はCAGR 7.1％で成長予測

米国の鼻用コルチコステロイド市場は、2024年に18億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに17億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.4%と2.9%と予測されています。欧州では、ドイツがCAGR 2.1%で成長すると予測されています。

世界の鼻用コルチコステロイド市場- 主要動向と促進要因のまとめ

鼻用コルチコステロイドが呼吸器治療薬やアレルギー管理に欠かせない理由とは？

鼻用コルチコステロイドは、鼻粘膜に対する強力な抗炎症作用により、アレルギー性鼻炎、慢性副鼻腔炎、鼻ポリープの治療の主役となっています。これらの副腎皮質ステロイドは、スプレーまたは点滴で投与され、アレルギー性または非アレルギー性の誘因によって引き起こされる鼻づまり、鼻水、くしゃみ、炎症を軽減するのに役立ちます。局所的な作用により全身的な副作用が最小限に抑えられるため、特に経口抗ヒスタミン薬や充血除去薬で十分な緩和が得られない場合に、上気道障害の長期的な対処法として使用されます。

フルチカゾン、モメタゾン、ブデソニド、ベクロメタゾン、トリアムシノロンなどのコルチコステロイドは、処方薬および市販薬（OTC）の両方でよく使用される薬剤です。これらの薬剤の使用範囲は、季節性アレルギー性鼻炎（花粉症）、通年性アレルギー、鼻ポリープ患者の術後維持など多岐にわたる。公害、気候変動、都市生活によるアレルギー症状の世界の増加に伴い、鼻用コルチコステロイドはますます欠かせないものとなってきています。また、局所的な免疫反応を調節し、粘膜の炎症を抑える能力を持つことから、COVID-19を含むウイルス性呼吸器感染症に対する補助的な役割も研究されています。

製剤の進歩と送達デバイスは、安全性、有効性、アドヒアランスをどのように向上させているのでしょうか？

経鼻コルチコステロイドデリバリーシステムにおける最近の技術革新は、鼻腔内への沈着を改善し、喉への刺激を最小限に抑え、投与量の精度を最適化することに重点を置いています。側方作動設計と超微細ミスト分散を備えた定量噴霧器は、使用者の快適性と有効性を高めるため、旧式のポンプ式デバイスに取って代わりました。進化したスプレーノズルは、鼻腔の鼻甲介の特定のゾーンをターゲットとし、より良好な粘膜被覆を確保し、旧世代のスプレーの使用者がよく訴える喉へのドリップバックを減少させています。

マイクロエマルジョンやリポソーム送達システムは、粘膜吸収を高め、滞留時間を延長し、必要な投与量を減らすために研究されています。防腐剤フリーの製剤は、特に慢性的な使用者や小児患者向けに普及しつつあります。さらに、1日1回投与レジメンと小児にやさしいアプリケーターは、慢性鼻炎患者の服薬アドヒアランスを向上させています。フルチカゾンやトリアムシノロンのような一般用医薬品は、消費者のアクセスやセルフケアの選択肢を増やす一方で、重度または併存する症状に対する処方薬は、耳鼻咽喉科やアレルギー専門医のもとで拡大し続けています。

鼻用コルチコステロイドの市場を拡大している患者層と地域は？

鼻用コルチコステロイドの中心的な患者層は、季節性または通年性のアレルギー性鼻炎患者、慢性副鼻腔炎患者、鼻ポリープや鼻手術後の炎症患者などです。小児科医は低用量で小児に安全なスプレーを選択しています。高齢者の使用者は、複数の合併症を抱えることが多く、全身性のコルチコステロイドにさらされることなく局所的に症状をコントロールする点鼻薬が有益です。

北米と西欧は最も成熟した市場であり、アレルギー有病率の高さ、OTCの普及率の高さ、医師による処方の広さがその要因となっています。アジア太平洋は、都市化、汚染レベル、アレルギー疾患に対する意識の高まりにより、著しい成長を遂げています。インド、中国、日本、韓国は、ブランドジェネリック医薬品と国際的なOTCブランドの両方が足跡を伸ばしている潜在力の高い市場です。ラテンアメリカと中東は、耳鼻咽喉科クリニック、薬局チェーン、呼吸器ケアプログラムを通じて需要が高まっています。

鼻用コルチコステロイド市場の長期的成長と治療イノベーションの原動力は？

鼻用コルチコステロイド市場の成長の原動力は、アレルギー発症率の上昇、長期使用における良好な安全性プロファイル、自己投与形式の改善です。一般開業医やアレルギー専門医の間で受け入れが進んでいることと、OTC移行に対する規制当局のサポートが相まって、これらの薬剤が広く利用されるようになっています。気候変動、花粉シーズン、室内汚染によるアレルギー性気道疾患の負担増は、対処可能な市場をさらに拡大しています。

治療法の革新は、多症状または抵抗性プロファイルを有する患者のために、抗ヒスタミン薬、充血除去薬、またはロイコトリエン拮抗薬を含む併用療法に向かって進んでいます。抗炎症薬と抗ヒスタミン薬の成分を含む二重作用の経鼻スプレーは、レジメンを簡略化するために開発中です。中枢神経系薬剤や免疫治療薬の経鼻デリバリーに関する調査も、副腎皮質ステロイドベースのプラットフォームに新たな可能性をもたらしています。製剤の改良と患者中心のデバイス設計への継続的な投資により、鼻用コルチコステロイドは世界の呼吸器疾患管理戦略の中心であり続けると思われます。

セグメント

薬剤タイプ（フルチカゾンプロピオン酸エステル、ブデソニド、ベクロメタゾンジプロピオン酸エステル、その他の薬剤タイプ）、適応症タイプ（アレルギー性鼻炎適応症、非アレルギー性鼻炎適応症）、タイプ（処方薬、市販薬）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（注目43社）

• AdvaCare Pharma
• AstraZeneca
• Bayer AG
• Cipla Limited
• Emergent BioSolutions Inc.
• Glenmark Pharmaceuticals
• GSK plc
• Intersect ENT Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• OptiNose US, Inc.
• Perrigo Company plc
• Pfizer Inc.
• Pharmascience Inc.
• Sanofi S.A.
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Nasal Corticosteroids Market to Reach US$8.4 Billion by 2030

The global market for Nasal Corticosteroids estimated at US$6.7 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Fluticasone Propionate, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.8 Billion by the end of the analysis period. Growth in the Budesonide segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 7.1% CAGR

The Nasal Corticosteroids market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global Nasal Corticosteroids Market - Key Trends & Drivers Summarized

Why Are Nasal Corticosteroids Essential in Respiratory Therapeutics and Allergy Management?

Nasal corticosteroids are a mainstay in the treatment of allergic rhinitis, chronic sinusitis, and nasal polyps due to their potent anti-inflammatory effects on the nasal mucosa. Administered via sprays or drops, these corticosteroids help reduce nasal congestion, runny nose, sneezing, and inflammation caused by allergic or non-allergic triggers. Their localized action minimizes systemic side effects, making them a preferred long-term management solution for upper airway disorders, particularly when oral antihistamines or decongestants fail to provide adequate relief.

Corticosteroids such as fluticasone, mometasone, budesonide, beclomethasone, and triamcinolone are commonly used agents in both prescription and over-the-counter (OTC) formulations. Their usage spans seasonal allergic rhinitis (hay fever), perennial allergies, and post-surgical maintenance in nasal polyp patients. With the global rise in allergic conditions due to pollution, climate change, and urban living, nasal corticosteroids are becoming increasingly indispensable. They are also being studied for adjunctive roles in viral respiratory infections, including COVID-19, given their ability to modulate local immune response and reduce mucosal inflammation.

How Are Formulation Advances and Delivery Devices Enhancing Safety, Efficacy, and Adherence?

Recent innovations in nasal corticosteroid delivery systems focus on improving deposition in the nasal cavity, minimizing throat irritation, and optimizing dose precision. Metered-dose sprays with side-actuated designs and ultra-fine mist dispersal have replaced older pump-action devices to enhance user comfort and efficacy. Advanced spray nozzles target specific zones of the nasal turbinates, ensuring better mucosal coverage and reduced drip-back into the throat, a common complaint among users of earlier generation sprays.

Microemulsion and liposomal delivery systems are being explored to enhance mucosal absorption, prolong residence time, and reduce required dosage. Preservative-free formulations, particularly for chronic users and pediatric populations, are gaining ground. Additionally, once-daily dosing regimens and child-friendly applicators have improved adherence in patients with chronic rhinitis. OTC availability of popular molecules like fluticasone and triamcinolone is increasing consumer access and self-care options, while prescription products for severe or comorbid conditions continue to expand under ENT and allergy specialist care.

Which Patient Demographics and Geographies Are Expanding the Market for Nasal Corticosteroids?

The core demographic for nasal corticosteroids includes individuals with seasonal or perennial allergic rhinitis, chronic sinusitis sufferers, and patients with nasal polyps or post-nasal surgery inflammation. Pediatric use is growing due to rising incidence of early-onset allergies and asthma, with pediatricians opting for low-dose, child-safe sprays. Geriatric users-often dealing with multiple comorbidities-benefit from nasal sprays that control symptoms locally without systemic corticosteroid exposure.

North America and Western Europe are the most mature markets, driven by high allergy prevalence, strong OTC penetration, and widespread physician prescribing. Asia-Pacific is witnessing significant growth due to increasing urbanization, pollution levels, and awareness about allergic diseases. India, China, Japan, and South Korea represent high-potential markets where both branded generics and international OTC brands are expanding footprint. Latin America and the Middle East are showing rising demand through ENT clinics, pharmacy chains, and respiratory care programs.

What Is Driving Long-Term Growth and Therapeutic Innovation in the Nasal Corticosteroids Market?

The growth in the nasal corticosteroids market is driven by rising allergy incidence, favorable safety profile for long-term use, and improvements in self-administered delivery formats. Greater acceptance among general practitioners and allergists, combined with regulatory support for OTC transitions, has made these drugs widely accessible. The rising burden of allergic airway diseases due to climate change, pollen seasons, and indoor pollution is further expanding the addressable market.

Therapeutic innovation is progressing toward combination therapies that include antihistamines, decongestants, or leukotriene antagonists for patients with multi-symptom or resistant profiles. Dual-acting intranasal sprays with anti-inflammatory and antihistaminic components are under development to simplify regimens. Research into nasal route delivery for CNS drugs and immunotherapies is also opening adjacent opportunities for corticosteroid-based platforms. With continued investment in formulation refinement and patient-centric device design, nasal corticosteroids will remain central to respiratory disease management strategies worldwide.

SCOPE OF STUDY:

The report analyzes the Nasal Corticosteroids market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate, Other Drug Types); Indication Type (Allergic Rhinitis Indication, Non-allergic Rhinitis Indication); Type (Prescription Drugs, Over-the-Counter Drugs); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

• AdvaCare Pharma
• AstraZeneca
• Bayer AG
• Cipla Limited
• Emergent BioSolutions Inc.
• Glenmark Pharmaceuticals
• GSK plc
• Intersect ENT Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• OptiNose US, Inc.
• Perrigo Company plc
• Pfizer Inc.
• Pharmascience Inc.
• Sanofi S.A.
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Nasal Corticosteroids - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Allergic Rhinitis Incidence Propels Growth in Nasal Corticosteroid Utilization
  • Expansion of OTC Accessibility Strengthens Business Case for Self-Administered Nasal Corticosteroids
  • Increased Prevalence of Chronic Rhinosinusitis Drives Demand for Long-Term Corticosteroid Therapy
  • Introduction of Once-Daily Formulations Enhances Patient Compliance and Drives Adoption
  • Innovation in Micro-Dosing Delivery Systems Spurs Market Expansion in Pediatric and Geriatric Segments
  • Surge in Asthma-Linked Nasal Symptoms Expands Addressable Market Opportunity for Nasal Corticosteroids
  • Growing Preference for Topical Over Systemic Therapies Accelerates Demand for Intranasal Formulations
  • Launch of Generic Fluticasone and Mometasone Variants Generates Competitive Pricing Opportunities
  • Rising Air Pollution Levels Amplify Demand for Anti-Inflammatory Nasal Treatments
  • Increased Emphasis on Symptom Management in ENT Care Supports Sustained Use of Nasal Corticosteroids
  • Proliferation of Digital Adherence Monitoring Tools Enhances Chronic Treatment Outcomes
  • Advancements in Propellant-Free Spray Technologies Strengthen Regulatory Compliance and Patient Safety
  • Expansion of Retail Pharmacies and E-Pharmacies Drives Distribution Efficiency
  • Rising Sensitization to Steroid-Related Side Effects Creates Need for Low-Potency Options
  • Regional Disparities in Treatment Access Create Gaps in Therapy Penetration
  • Integration of Nasal Corticosteroids in Multi-Modal Respiratory Treatment Regimens Spurs Market Expansion
  • Availability of Combination Formulations with Antihistamines Broadens Product Utility
  • Government Guidelines Recommending Early Intervention Propel Preventive Use Cases
  • Increased Demand for Preservative-Free Formulations Enhances Product Acceptability in Sensitive Populations
  • Growing Focus on Clinical Trial Outcomes and Real-World Evidence Validates Therapeutic Efficacy
  • Stringent Prescription-to-OTC Transition Regulations Pose Challenges for Market Entrants
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Nasal Corticosteroids Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Nasal Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Nasal Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Nasal Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Fluticasone Propionate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Fluticasone Propionate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Fluticasone Propionate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Budesonide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Budesonide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Budesonide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Beclomethasone Dipropionate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Beclomethasone Dipropionate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Beclomethasone Dipropionate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Allergic Rhinitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Allergic Rhinitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Allergic Rhinitis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Non-allergic Rhinitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Non-allergic Rhinitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Non-allergic Rhinitis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Prescription Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Prescription Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Over-the-Counter Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Over-the-Counter Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• JAPAN
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• CHINA
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• EUROPE
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Nasal Corticosteroids by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Nasal Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• FRANCE
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• GERMANY
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Nasal Corticosteroids by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• INDIA
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Nasal Corticosteroids by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Nasal Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Nasal Corticosteroids by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Nasal Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030
• AFRICA
  • Nasal Corticosteroids Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Nasal Corticosteroids by Drug Type - Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Nasal Corticosteroids by Drug Type - Percentage Breakdown of Value Sales for Fluticasone Propionate, Budesonide, Beclomethasone Dipropionate and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Nasal Corticosteroids by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Nasal Corticosteroids by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Nasal Corticosteroids by Indication Type - Allergic Rhinitis Indication and Non-allergic Rhinitis Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Nasal Corticosteroids by Indication Type - Percentage Breakdown of Value Sales for Allergic Rhinitis Indication and Non-allergic Rhinitis Indication for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Nasal Corticosteroids by Type - Prescription Drugs and Over-the-Counter Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Nasal Corticosteroids by Type - Percentage Breakdown of Value Sales for Prescription Drugs and Over-the-Counter Drugs for the Years 2015, 2025 & 2030

IV. COMPETITION